NCT01531569View on ClinicalTrials.gov

Single Oral Dose of BeneFlax to Healthy Young and Older Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Diabetes Mellitus, Type 2Hypercholesterolemia
Interventions
OTHER

BeneFlax - 38% secoisolariciresinol diglucoside (SDG)

0.8g of BeneFlax (contains 300mg SDG) given once by mouth

Trial Locations (1)

S7K 0M7

Saskatoon Centre for Patient Oriented Research - Saskatoon City Hospital, Saskatoon

All Listed Sponsors
collaborator

Saskatchewan Health Research Foundation

OTHER

lead

University of Saskatchewan

OTHER

NCT01531569 - Single Oral Dose of BeneFlax to Healthy Young and Older Adults | Biotech Hunter | Biotech Hunter